Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 22, 2007

Eisai Makes a $325M Leap into Biologics Market by Acquiring Morphotek

  • Eisai plans to enter the biologic therapeutics field through a $325-million acquisition of Morphotek.

    The company believes it can hone its focus on addressing unmet medical needs, especially those of cancer patients. Eisai expects to pad its small molecule driven oncology research program with Morphotek's technologies and therapeutic Mabs.

    Eisai plans on closing the transaction sometime during its first fiscal quarter of 2007.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »